FDA Approves First Generics for Common Multiple Sclerosis Drug

FDA Approves First Generics for Common Multiple Sclerosis Drug

Publication date: Dec 06, 2019

These are the first generics of the drug, which treats relapsing forms of multiple sclerosis (MS) in adult patients. The approvals were granted to HEC PharmD Co. Limited, Biocon Limited, and Sun Pharmaceutical Industries Limited. MS is a chronic, inflammatory autoimmune disease that disrupts communication between the brain and other parts of the body. It is one of the most common causes of neurological disability in young adults. According to the National Multiple Sclerosis Society, the disease is believed to affect nearly 1 million adults in the United States.

Concepts Keywords
Abdominal Pain Novartis
Autoimmune Medicine
Biocon Fingolimod
Brain Diols
Capsules Multiple sclerosis
Clinical Trials Immunology
Common Immunosuppressants
Cough Medical specialties
Diarrhea Inflammatory
Disability MS
FDA Cough influenza sinusitis
Fingolimod Pain abdominal pain
Generics Sphingosine-1-phosphate receptor modulator
Gilenya
Headache
Heart Rate
HEC
Influenza
Liver
Multiple Sclerosis
Neurological
Novartis
Pain
PharmD
Progressive
Sinusitis
United States

Semantics

Type Source Name
disease MESH back pain
disease MESH sinusitis
disease MESH influenza
disease MESH relapses
disease MESH men
disease MESH autoimmune disease
drug DRUGBANK Fingolimod
disease MESH Multiple Sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *